UnitedHealth Group Incorporated (UNH)
UnitedHealth: Time To Buy This Healthcare Fortress
UnitedHealth Group is rated Buy, with the worst seemingly behind and a clear path to margin recovery and earnings growth from 2026 onward. UNH's 2025 headwinds - higher medical expense ratio, Medicare Advantage pressures, and regulatory scrutiny - are being addressed through repricing, plan exits, and portfolio optimization. Valuation remains compelling: UNH trades at multi-year low multiples, with intrinsic value estimated at $843.55 per share, implying 154% upside.
Is UnitedHealth's Valuation Dip & Divestment Diet a Real Buy Window?
UNH trades below its five-year median P/E as it navigates margin pressure, membership declines and strategic divestments.
UnitedHealth Group (UNH) Sees a More Significant Dip Than Broader Market: Some Facts to Know
UnitedHealth Group (UNH) closed at $323.21 in the latest trading session, marking a -1.99% move from the prior day.
UnitedHealth: Axing Another Distraction, Onto 2026
UnitedHealth Group Incorporated is positioned for a multi-year turnaround, with 2026 marking the inflection and 2027 expected to deliver significant margin expansion. UNH's exit from Latin America, including a $1 billion Banmedica sale, strengthens the balance sheet and supports dividends and future buybacks. Despite elevated medical cost ratios and recent earnings pressure, UNH's Q3 revenue grew 12.3%, and management raised 2025 EPS guidance to at least $16.25.
Mangione shown videos of UnitedHealthcare CEO killing in court
Luigi Mangione has watched surveillance videos of the killing of UnitedHealthcare CEO Brian Thompson at a court appearance.
UnitedHealth agrees to sell South American business to private equity firm Patria for $1 billion, sources say
UnitedHealth Group has agreed to sell its last South American business Banmedica to Brazilian private equity group Patria Investments for $1 billion, two sources with knowledge of the matter said on Sunday.
UNH Battles MCR, Optum Bandages: But the Real Wild Card is Washington
UnitedHealth grapples with a surging MCR as Optum's strength steadies results while Washington's policy moves loom large.
Battle of Benefits: Will UNH Deliver the Bigger Dose or CVS? (Revised)
CVS's rising margins, stronger guidance and sharper valuation edge make it stand out in the UNH vs. CVS upside debate.
Battle of Benefits: Will UNH Deliver the Bigger Dose or CVH?
CVS's rising margins, stronger guidance and sharper valuation edge make it stand out in the UNH vs. CVS upside debate.
Is UNH's Hybrid Care Strategy Reshaping the Health System Playbook?
UnitedHealth pushes its hybrid care model forward, merging digital tools with in-person care as it extends this approach across global markets.
Why Did UNH Stock Lose Half Its Value And What Comes Next?
UnitedHealth's stock plummeted from over $600 to approximately $310-$320 (nearly 50% down) over the last year, and it's not merely market fluctuations. This decline stems from a significant issue centered around one key metric: the Medical Care Ratio (MCR).
UnitedHealth Group (UNH) Beats Stock Market Upswing: What Investors Need to Know
UnitedHealth Group (UNH) concluded the recent trading session at $319.97, signifying a +2.71% move from its prior day's close.
